Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Recent advances in understanding and managing T-cell lymphoma.

Yi JH, Kim SJ, Kim WS.

F1000Res. 2017 Dec 12;6:2123. doi: 10.12688/f1000research.12573.1. eCollection 2017. Review.

2.

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Xu-Monette ZY, Zhou J, Young KH.

Blood. 2018 Jan 4;131(1):68-83. doi: 10.1182/blood-2017-07-740993. Epub 2017 Nov 8. Review.

PMID:
29118007
3.

Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma.

Matsumoto Y, Nagoshi H, Yoshida M, Kato S, Kuroda J, Shimura K, Kaneko H, Horiike S, Nakamura S, Taniwaki M.

Intern Med. 2017 Nov 1;56(21):2851-2856. doi: 10.2169/internalmedicine.8570-16. Epub 2017 Sep 25.

4.

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ.

Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.

PMID:
28893733
5.

Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, Schoppmann SF.

Ann Surg Oncol. 2017 Sep;24(9):2698-2706. doi: 10.1245/s10434-017-5858-7. Epub 2017 Apr 20.

6.

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y.

Medicine (Baltimore). 2017 Apr;96(15):e6398. doi: 10.1097/MD.0000000000006398.

7.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

8.

PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, Woods GM, Hayball JD.

Front Immunol. 2016 Dec 9;7:581. doi: 10.3389/fimmu.2016.00581. eCollection 2016.

9.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Hude I, Sasse S, Engert A, Bröckelmann PJ.

Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24. Review.

11.

Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma.

Zhou Y, Rosenblum MK, Dogan A, Jungbluth AA, Chiu A.

J Hematop. 2015 Dec;8(4):235-241. Epub 2015 Mar 18.

12.

Activation of intrahepatic CD4+CXCR5+ T and CD19+ B cells is associated with viral clearance in a mouse model of acute hepatitis B virus infection.

Song XF, Hu TT, Lei Y, Li H, Zhang L, Zhang M, Liu B, Chen M, Hu HD, Ren H, Hu P.

Oncotarget. 2016 Aug 9;7(32):50952-50962. doi: 10.18632/oncotarget.10688.

13.

Insights into the development and regulation of T follicular helper cells.

Wali S, Sahoo A, Puri S, Alekseev A, Nurieva R.

Cytokine. 2016 Nov;87:9-19. doi: 10.1016/j.cyto.2016.06.010. Epub 2016 Jun 20. Review.

14.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Ma W, Gilligan BM, Yuan J, Li T.

J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.

15.

Common Variable Immunodeficiency and Circulating TFH.

Coraglia A, Galassi N, Fernández Romero DS, Juri MC, Felippo M, Malbrán A, de Bracco MM.

J Immunol Res. 2016;2016:4951587. doi: 10.1155/2016/4951587. Epub 2016 Mar 16.

16.

PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Guan H, Lan Y, Wan Y, Wang Q, Wang C, Xu L, Chen Y, Liu W, Zhang X, Li Y, Gu Y, Wang Z, Xie F.

Oncoimmunology. 2015 Aug 12;5(2):e1075112. eCollection 2016 Feb.

17.

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K.

Blood. 2015 Nov 5;126(19):2193-201. doi: 10.1182/blood-2015-02-629600. Epub 2015 Aug 3.

18.

Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.

Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N.

Am J Cancer Res. 2015 Mar 15;5(4):1553-7. eCollection 2015.

19.

Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA.

Am J Dermatopathol. 2015 Aug;37(8):604-13. doi: 10.1097/DAD.0000000000000266.

20.

Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.

Cai Q, Chen K, Young KH.

Exp Mol Med. 2015 Jan 23;47:e133. doi: 10.1038/emm.2014.105. Review.

Supplemental Content

Support Center